News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association


6/16/2014 10:46:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from AML-001, its phase III study of VIDAZA® (azacitidine for injection) compared to conventional care regimens (CCR) in elderly subjects with newly-diagnosed acute myeloid leukemia (AML - >30% blasts) were presented in a late-breaking abstract oral session at the 19th European Hematology Association annual congress. The study was presented by Pr. Hervé Dombret of the Hôpital Saint-Louis in Paris, France.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES